Aileron Therapeutics Q4 EPS $(1.54) Down From $(1.00) YoY; Cash Runway Expected To Fund Operations And Key Milestones Into Q4 Of 2024
Company Profile
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.